Catalent’s planning service is designed to assist in evaluating needs for launching and maintaining clinical trials.
Catalent announced the launch of the CTSuccess clinical trial planning service that uses a proprietary evaluation tool to calculate the complexity of a potential clinical project across more than a dozen specific and objective study characteristics.
The StartScore model is based on actual performance data which generates a risk-based score to help sponsors understand the appropriate level of clinical supply management oversight needed to start a project on time and maintain momentum as the study progresses, the company reported in a Dec. 12, 2019 press announcement.
“No two studies are the same, and each carries its own unique risks and presents individual challenges, but the aim of CTSuccess is to use the experience we have as a company in supplying materials for thousands of trials to identify the characteristics of a project upfront and highlight potential risk factors that may arise,” commented Kristen Devito, global director, Catalent Clinical Supply Services in the press statement. “Once these risks have been identified then a project team can be put together combining the necessary expertise to provide the integrated services and tailored support to ensure continuity of supply from beginning to end.”
The company’s clinical supply network includes nine cGMP-certified clinical packaging facilities across North America, Europe, and Asia, and more than 50 depots around the world. The facilities provide local and regional options for clinical storage, distribution, expiry update and relabeling services, and clinical returns management, the company reports.
Source: Catalent
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.